Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2016

View Archived Issues

vTv Therapeutics describes HK-2 inhibitors

SAMHD1, a novel biomarker for cytarabine response and therapeutic target in AML

Ebola vaccine rVSV-ZEBOV shows promising results in clinical trial

Pharmacyclics patents BTK inhibitors

Merck & Co. and MSD R&D disclose PDE2A inhibitors

OncoMed Pharmaceuticals reports phase Ia results on OMP-305B83

Scientists report phase II data for selinexor in patients with MM

Investigators present preliminary phase II results of SL-401 in AML patients

BAX-930 shows potential in patients with hereditary thrombotic thrombocytopenic purpura

Columbia University Medical Center sponsors clinical study using Biocept's liquid biopsy platform

FDA expands indications for Shire's Adynovate

NIPTE forms part of a newly announced National Biopharmaceutical Manufacturing Institute

Prana offers update on development portfolio

Bioinformatics confirms GM6 as a regulator of ALS- and AD- relevant pathways

DynPort Vaccine Company receives contract to help advance medical products for NIAID

Capnia and Essentialis sign merger agreement

World's only recombinant monovalent acellular Pertussis vaccine receives Thai FDA approval

Anthera reports topline data from phase III study of Sollpura

FDA puts clinical hold on several early-stage trials of vadastuximab talirine

OSE Immunotherapeutics signs worldwide license option agreement with Servier for Effi-7

U.S. and China IND clearances for Ascentage's APG-1252

Ono seeks Japanese approval of Opdivo in gastric cancer

Phase III results for padeliporfin vascular-targeted photodynamic therapy in prostate cancer

Immunomedics' phase II study of sacituzumab govitecan reaches planned enrollment

Escend Pharmaceuticals' tetrandrine gets FDA orphan designation for AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...